The global endoscopic retrograde cholangiopancreatography market size reached US$ 1.38 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.11 Billion by 2027, exhibiting a growth rate (CAGR) of 7.20% during 2022-2027.

Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging technique that diagnoses and treats abnormalities in the liver, gallbladder, bile ducts, and pancreas. It combines X-rays and a long, flexible, lightweight endoscope tube that passes through the esophagus, mouth, and stomach. It helps detect blockages, stones, infections, and tumors in the bile duct and fluid leakage from the pancreatic duct. Besides this, it is a less invasive procedure than open surgery and provides more detailed and accurate information about the pancreaticobiliary system. As a result, the demand for endotherapy devices is increasing across the globe to investigate dysphagia, diarrhea, weight loss, heartburn, and stool blood.

Endoscopic Retrograde Cholangiopancreatography Market Trends:
The growing global population and the rising prevalence of various chronic gastrointestinal (GI) and incessant biliary medical disorders, including Barrett’s disease, biliary, liver, Crohn’s, inflammatory bowel, and peptic ulcer disease, and gastroesophageal reflux disorder (GERD), represent one of the key factors positively influencing the market. In addition, the increasing occurrence of benign pancreas and liver tumors, especially among the geriatric population, along with the growing occurrence of cancer across the globe, is driving the market. In line with this, the expansion of hospitals and diagnostic centers is increasing the need for imaging techniques propelling the market growth. Furthermore, rising investments by governments and healthcare organizations of various countries in advanced endoscopy devices and improve endoscopy research is strengthening the market growth. Apart from this, the shifting consumer preference toward minimally invasive surgeries for a speedy recovery and minimal pain and rising awareness about ERCP devices like sphincterotomes are offering a favorable market outlook. Moreover, continuous improvements in healthcare infrastructure and a considerable rise in medical tourism are expected to propel market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global endoscopic retrograde cholangiopancreatography market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, procedure and end user.

Breakup by Product:

Endoscope
Endotherapy Devices
Sphincterotomes
Lithotripter
Stents
Others
Visualization Systems
Energy Devices
Others

Breakup by Procedure:

Biliary Sphincterotomy
Biliary Stenting
Biliary Dialtation
Pancreatic Sphincterotomy
Pancreatic Duct Stenting
Pancreatic Duct Dilatation

Breakup by End User:

Hospitals and Clinics
Ambulatory Surgery Centers
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc.

Key questions answered in this report:
How has the global endoscopic retrograde cholangiopancreatography market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global endoscopic retrograde cholangiopancreatography market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the procedure?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global endoscopic retrograde cholangiopancreatography market and who are the key players?
What is the degree of competition in the industry?